Synta Pharmaceuticals (SNTA) (6.34 -1.46)
Synta Pharmaceuticals Corp. (SNTA) on Thursday filed with the Securities and Exchange Commission to sell up to $150 million in mixed securities from time to time. The Lexington, Mass., biopharmaceutical company said the mixed securities include common and preferred stock, debt securities, warrants and units. Synta said it intends to use the net proceeds from the sale of the securities for general corporate purposes, which may include the repayment or refinancing of debt. It may also use proceeds for working capital, intellectual property protection and enforcement, capital expenditures, investments, acquisitions, repurchases of securities, and research and development and product development. No underwriters were listed in Thursday's SEC filing. Synta is focused on developing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases (Dow Jones Newswires 06:33 AM ET 08/07/2008 More...) |
